Type 2 Diabetes

At ADA 2023, hosts sit down with Gary Rothenberg, DPM, to discuss awareness and management of diabetic foot ulcers as well as how social determinants of health can influence risk and outcomes for patients with diabetes.

At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

A meta-analysis of 13 trials suggests SGLT2 inhibitors reduced heart failure events and cardiovascular death across these patient populations, with consistent effects in patients with varying disease combinations.

An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.

The FDA's historic June 20, 2023 approval of empagliflozin (Jardiance) and empagliflozin plus metformin hydrochloride (Synjardy) marks the first pediatric type 2 diabetes indication for the SGLT2 inhibitor class and comes less than a year after the debut of DINAMO data.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

The investigative team observed a U-shaped relationship between sleep duration and incident diabetes, with the greatest risk when sleep duration was ≥10 hours per day.

Among more than 80,000 older adults with T2D and established CVD, those in the highest quartile of out-of-pocket costs were less likely to initiate a GLP-1 R or SGLT2 inhibitor.

During a presentation at the Metabolic Insitute of America's 7th Heart in Diabetes meeting, Erin Michos, MD, broke down the importance of recognizing the bidirectional risk between diabetes and menopause.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.

A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.

An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.

Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.

The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

As a follow-up to an episode earlier this year and the FDA clearances of the technology that forms the iLet Bionic Pancreas, hosts sat down in the MJH Life Sciences studio for a special edition recording to explore the implications of the clearance, dispel misconceptions surrounding the system, and hypothesize about the future of this technology in people with diabetes.

An analysis of data from the ARIC study is offering new insight into the impact of age at diabetes onset on the risk of developing dementia later in life.

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

In this episode, hosts sit down for an in-depth discussion of the 11 person-centered algorithms for clinical decision-making featured in the AACE's 2023 Comprehensive Type 2 Diabetes Management Algorithm.

In a recent interview, Kris Kowdley, MD, discusses current data surrounding use of GLP-1 receptor agonists in NAFLD and NASH as well as the prospective role of combination agents.